All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

June 30th 2025

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

KN026 With KN046 Shows Durable Responses in Pretreated HER2+ Breast Cancer

June 30th 2025

Treatment with KN026 plus KN046 demonstrated durable responses and a manageable safety profile in previously treated HER2-positive breast cancer.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

FDA Grants Breakthrough Therapy Designation to Daraxonrasib for KRAS G12X-Mutant Metastatic PDAC

June 29th 2025

Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer

June 28th 2025

IBI354 continued to demonstrate tolerability and was active in pretreated, HER2-positive advanced breast cancer.

Tigilanol Tiglate Shows Early Efficacy in Soft Tissue Sarcomas

June 27th 2025

Data from the first stage of a phase 2a study suggest that tigilanol tiglate reduced tumor volume in patients with soft tissue sarcoma.

Encorafenib/Binimetinib/Nivolumab Improves PFS in BRAF V600+ Melanoma with Symptomatic Brain Metastases

June 27th 2025

Encorafenib plus binimetinib and nivolumab improved PFS in BRAF V600–mutant melanoma with symptomatic brain metastases.

Elraglusib Plus Chemotherapy Extends OS vs Chemotherapy Alone in Frontline Metastatic PDAC

June 27th 2025

Elraglusib plus gemcitabine and nab-paclitaxel lead to an OS benefit vs chemotherapy alone in treatment-naive metastatic PDAC.

Presurgical Radiation Therapy May Offer Alternative Approach to Treating Brain Metastases

June 27th 2025

Studies have suggested that pre-surgical SRT may be comparable to standard post-surgical SRT in patients with resectable brain metastases.

Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC

June 27th 2025

Zidesamtinib, a selective ROS1 inhibitor, was well tolerated and showed antitumor activity in pretreated, advanced ROS1-positive NSCLC.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Tivozanib Monotherapy May Serve as Effective Second-Line Option in Metastatic RCC

June 27th 2025

Alexander Chehrazi-Raffle, MD, discusses the efficacy of tivozanib monotherapy after receipt of upfront IO/TKI or ipilimumab/nivolumab in RCC.

TQB2102 Generates Antitumor Activity in Pretreated HER2-Low Breast Cancer

June 27th 2025

The bispecific antibody-drug conjugate TQB2102 was safe and active in pretreated, recurrent or metastatic, HER2-positive breast cancer.

Obrixtamig Leverages DLL3 Targeting to Offer a Potential Treatment Option in Extrapulmonary Neuroendocrine Carcinoma

June 27th 2025

Balazs Halmos, MD, discusses the DLL3-targeted BiTE obrixtamig for the treatment of patients with extrapulmonary neuroendocrine carcinoma.

JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma

June 26th 2025

The trispecific antibody JNJ-5322 showed preliminary efficacy and safety signals in BCMA- and GPRC5D-naive relapsed/refractory myeloma.

ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma

June 26th 2025

ALLO-316 showed activity and a tolerable safety profile in patients with pretreated advanced or metastatic clear cell renal cell carcinoma.

Advances in Immunotherapy Necessitate Nuanced Understanding of Clinical Application Across Tumor Types

June 26th 2025

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.